Next Article in Journal / Special Issue
The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy
Previous Article in Journal / Special Issue
Cases of Adverse Reaction to Psychotropic Drugs and Possible Association with Pharmacogenetics
Open AccessArticle

Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing

Generation Health, 130 Turner St., Waltham, MA 02453, USA
TESARO Inc., 1000 Winter St. Suite 3300, Waltham, MA 02451, USA
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, 1620 Tremont St., Suite 3030, Boston, MA 02120, USA
ZIOPHARM Oncology, Inc., 1 First Avenue, Parris Building, #34, Navy Yard Plaza, Boston, MA 02129, USA
CVS Caremark, One CVS Drive, Woonsocket, RI 02895, USA
Author to whom correspondence should be addressed.
J. Pers. Med. 2012, 2(4), 158-174;
Received: 28 August 2012 / Revised: 1 October 2012 / Accepted: 10 October 2012 / Published: 17 October 2012
HMG-CoA reductase inhibitors, commonly known as statins, are some of the most widely prescribed medications worldwide and have been shown to be effective at lowering cholesterol in numerous long-term prospective trials, yet there are significant limitations to their use. First, patients receiving statin therapy have relatively low levels of medication adherence compared with other drug classes. Next, numerous statin formulations are available, each with its own unique safety and efficacy profile, and it may be unclear to prescribers which treatment is optimal for their patients. Finally, statins have class-wide side effects of myopathy and rhabdomyolysis that have resulted in a product recall and dosage limitations. Recent evidence suggests that two genomic markers, KIF6 and SLCO1B1, may inform the therapy choice of patients initiating statins. Given the prevalence of statin usage, their potential health advantages and their overall cost to the healthcare system, there could be significant clinical benefit from creating personalized treatment regimens. Ultimately, if this approach is effective it may encourage higher adoption of generic statins when appropriate, promote adherence, lower rates of myopathy, and overall achieve higher value cardiovascular care. This paper will review the evidence for personalized prescribing of statins via KIF6 and SLCO1B1 and consider some of the implications for testing these markers as part of routine clinical care. View Full-Text
Keywords: statins; adherence; myopathy; KIF6; SLCO1B1 statins; adherence; myopathy; KIF6; SLCO1B1
Show Figures

Figure 1

MDPI and ACS Style

Canestaro, W.J.; Brooks, D.G.; Chaplin, D.; Choudhry, N.K.; Lawler, E.; Martell, L.; Brennan, T.; Wassman, E.R. Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. J. Pers. Med. 2012, 2, 158-174.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop